This is a busy time Avidity Biological SciencesThe La Jolla, California-based company went public during Covid last year and is preparing to start a Phase 1/2 clinical trial before the end of 2021 to test its treatment of myotonic dystrophy, a rare genetic disease of muscles. New antibody-oligonucleotide conjugates. There is currently no treatment for myotonic dystrophy.
For Sarah Boyce, the company’s CEO, seeing the successful business path of her treatment candidates may be as important as the diversity and inclusion culture she is committed to building in the company. The number of men and women on the Avidity board of directors is equal. In this episode of MedCity’s Pivot podcast, Boyce emphasized that she is now committed to creating a workplace where women can feel empowered and thrive when men mistakenly believe she is responsible for recording meeting minutes or telling her what to wear. In An epiphany at the annual JPMorgan Chase Healthcare Conference.
